Hyperbaric Oxygen Therapy for Long COVID Relief in Concord, CA

Long COVID — formally termed Post-Acute Sequelae of SARS-CoV-2 (PASC) — is defined as the persistence of symptoms for four or more weeks after the acute phase of COVID-19 infection, without another explanation. Studies estimate that 10 to 30% of all people infected with COVID-19 develop Long COVID, representing tens of millions of patients worldwide. In the Bay Area, where COVID rates were high and health awareness is strong, significant numbers of otherwise healthy, high-functioning adults have found their lives profoundly disrupted by this condition.

Research has identified several overlapping biological mechanisms driving Long COVID. These include persistent viral reservoirs (remaining fragments of SARS-CoV-2 RNA in gut, lymph nodes, or other tissues), widespread endothelial damage (injury to the cells lining blood vessels throughout the body), microclot formation in small vessels that reduces oxygen delivery to tissues, chronic neuroinflammation affecting brain structure and function, and mitochondrial dysfunction leading to impaired cellular energy production. The result is a multi-system syndrome that does not respond well to treatments aimed at a single mechanism.

Long COVID does not discriminate by age or prior health status — many patients were young, fit, and vaccinated before their infection. The wide spectrum of symptoms, their often fluctuating course, and the absence of definitive biomarkers have made diagnosis and treatment deeply challenging within conventional medicine frameworks.

HBOT is one of the few therapeutic approaches that addresses multiple Long COVID mechanisms simultaneously, rather than targeting a single symptom or pathway.

In a pressurized hyperbaric chamber at 1.5 to 2.5 atmospheres, breathing 100% pure oxygen raises plasma oxygen concentrations 10 to 15 times above normal. This elevated systemic oxygen directly corrects the tissue hypoxia caused by microclots and endothelial dysfunction — restoring oxygen delivery to brain, muscle, and organ tissue that has been chronically starved. It also promotes the dissolution of the fibrin-rich microclots that research teams at the University of Stellenbosch and elsewhere have identified in Long COVID patients' blood.

Beyond oxygenation, HBOT triggers a powerful anti-inflammatory cascade: it downregulates NF-κB (a central driver of chronic inflammation), reduces pro-inflammatory cytokines, and suppresses neuroinflammation in the regions of the brain most affected by Long COVID. A landmark randomized controlled trial published in Nature Communications in 2022 demonstrated that HBOT significantly improved cognitive function, energy levels, sleep quality, and pain scores in Long COVID patients compared to sham treatment, with MRI evidence of increased brain perfusion in the treated group. HBOT also stimulates mitochondrial biogenesis — directly addressing the energy production failure that drives post-exertional malaise — and promotes neuroplasticity, supporting recovery of neural circuits disrupted by viral neuroinvasion. Dr. Toth designs individualized HBOT protocols for Long COVID patients, typically 40 sessions, adjusted to each patient's specific symptom profile and tolerance.